Rifaldazine

Alzheimer Disease

Bristol-Myers SquibbSmall moleculePhase 3Dormant

B

61/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 55/ 100
Competitive Position: 73/ 100

Competitive context

299 Active assets in the Alzheimer Disease cohort.

Asset / Sponsor	Phase	Rating
4-((1E)-2-(6-(2-)2-(2-FLUOROETHOXY)ETHOXY)ETHOXY)PYRIDIN-3-YL)ETHENYL)-N-METHYLBENZENAMINE Akiva Mintz	Phase 4	BBB
Memantine Carnot Laboratories	Phase 4	BBB
Escitalopram NYU Langone Health	Phase 4	BBB
FLORTAUCIPIR Eli Radiopharma	Phase 4	BBB
Rivastigmine Anhui Provincial Hospital	Phase 4	BBB

View all 50 →

Same molecule, other indications

Rifaldazine is also rated in:

methicillin-resistant staphylococcus aureus infectious diseaseDormant

BB

Indicative · Phase 4

71 / 100

cystic fibrosisDormant

BB

Indicative · Phase 4

65 / 100

metabolic dysfunction-associated steatotic liver diseaseDormant

B

Indicative · Phase 4

62 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.